By Stephen Nakrosis

Vanda Pharmaceuticals said the Food and Drug Administration accepted the filing of the company's new drug application for tradipitant to treat symptoms of gastroparesis.

Gastroparesis is characterized by delayed gastric emptying with symptoms including bloating, nausea, vomiting and abdominal pain, the company said Monday.

Vanda said about 6 million patients in the U.S. have gastroparesis, many of whom remain undiagnosed.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 04, 2023 18:30 ET (23:30 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Vanda Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Vanda Pharmaceuticals 차트를 더 보려면 여기를 클릭.